Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Bosutinib + Palbociclib + Fulvestrant for Advanced Breast Cancer
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is designed to study the safety of a new cancer drug and to see if it works. The drug will be given to patients 5 days a week, with 2 days off, and the dose will be increased gradually to ensure safety. The study will enroll patients in groups of 3, and will observe them for 28 days to see if there are any side effects. If the drug is found to be safe and effective, patients will be able to continue treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.